US stock movement: Arcutis surged on October 9 due to ZORYVE data and infant eczema news

Arcutis October 9 Surge Analysis

Keywords: ZORYVE data, infant eczema

1. On October 9, the company released data from the Phase II INTEGUMENT-INFANT trial of ZORYVE cream 0.05% in infants aged 3 to under 24 months with atopic dermatitis, showing that once-daily treatment achieved positive results, covering infant patients with limited treatment options.

2. On October 9, the company released new analyses from the ARRECTOR and DERMIS-1/2 trials, indicating that both ZORYVE cream and foam formulations can improve symptoms, skin clearance, and quality of life for patients with psoriasis, covering different areas of the body.

(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)